CN101390970B - Traditional Chinese medicine for treating hepatitis B and preparation method thereof - Google Patents
Traditional Chinese medicine for treating hepatitis B and preparation method thereof Download PDFInfo
- Publication number
- CN101390970B CN101390970B CN2008102335220A CN200810233522A CN101390970B CN 101390970 B CN101390970 B CN 101390970B CN 2008102335220 A CN2008102335220 A CN 2008102335220A CN 200810233522 A CN200810233522 A CN 200810233522A CN 101390970 B CN101390970 B CN 101390970B
- Authority
- CN
- China
- Prior art keywords
- liver
- chinese traditional
- traditional medicine
- medicine
- extractum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 238000007796 conventional method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000005242 forging Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 238000001354 calcination Methods 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000006870 function Effects 0.000 abstract description 7
- 241000700721 Hepatitis B virus Species 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 abstract description 4
- 208000006454 hepatitis Diseases 0.000 abstract description 4
- 206010016654 Fibrosis Diseases 0.000 abstract description 3
- 230000001914 calming effect Effects 0.000 abstract description 3
- 230000004761 fibrosis Effects 0.000 abstract description 3
- 230000017074 necrotic cell death Effects 0.000 abstract description 3
- 241001183967 Isodon Species 0.000 abstract description 2
- 240000001659 Oldenlandia diffusa Species 0.000 abstract description 2
- 241001248672 Rhinacanthus Species 0.000 abstract description 2
- 206010019692 hepatic necrosis Diseases 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 208000018191 liver inflammation Diseases 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- -1 troche Substances 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 231100000012 chronic liver injury Toxicity 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 208000000197 Acute Cholecystitis Diseases 0.000 description 2
- 206010008614 Cholecystitis acute Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001625898 Mauritia arabica Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Chemical class CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000984599 Cypraeidae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241000124879 Grus leucogeranus Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241001648835 Polygonum cuspidatum Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 240000002396 Rhinacanthus nasutus Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese Traditional Medicine for treating hepatitis B, which is characterized in that the Chinese Traditional Medicine is composed of following raw materials by weight percentage: 20 to 60 percent of twig and leaf of bignose rhinacanthus, 20 to 45 percent of linearstripe rabdosia herb, 7 to 15 percent of concha mauritiae, 5 to 20 percent of rhiaoma polygoni cuspidati and 8 to 20 percent of spreading hedyotis herb. The Chinese Traditional Medicine has the functions of invigorating the liver and the kidney, removing heat and toxin from liver and calming liver and suppressing liver-yang; and can prevent the hepatitis B virus from replicating, alleviate the liver inflammation and necrosis, protect the liver cells from fibrosis, improve the liver regeneration, delay and resist the repeated attacks which may result in illness exacerbation by begetting hepatocirrhosis and liver cancer. By utilizing the unique composite theory, cure principle and reasonable prescription combination in the Chinese Traditional Medicine, the Chinese Traditional Medicine adopts the pure Chinese Traditional Medicine for oral usage to cure hepatitis B with security, simplicity and fine curative effect. The Chinese Traditional Medicine can be made into granular formulation, troche, capsule and oral liquid with convenient use. The preparing method of the Chinese Traditional Medicine is scientific and reasonable with less loss of effective component and high extracting ratio.
Description
Technical field
The present invention relates to a kind of Chinese medicine of treating hepatitis B, belong to biological pharmacy technical field.
Background technology
Hepatitis B virus (Hepatitis B virus HBV) is one of human modal viral infection, and part crowd can not thoroughly remove virus behind the actute infection hepatitis B virus, formed chronic hepatitis B (Chronichepatitis B, CHB).Add up according to World Health Organization (WHO); Nearly 2,000,000,000 people in the whole world infected HBV; The 3.5 hundred million people person that develops into the chronic hbv-infection wherein; Annual have 500,000 to 1,200,000 people to die from liver failure, liver cirrhosis and primary hepatoma (HCC) due to the hepatitis B PD approximately, and hepatitis B has become the tenth-largest killer of harm humans life.China is the hepatitis B district occurred frequently, and there are 1.2 hundred million HBV carriers in the whole nation according to the preliminary statistics, nearly has that 300,000 people die from relevant disease an every year, and the hepatitis B control brings great challenge to Chinese society.
But the control of hepatitis B and treatment all do not have the breakthrough of essence for a long time.Present used hepatitis B virus resisting medicine such as interferon, its curative effect is limited, and untoward reaction is bigger; Though the nucleosides material antivirus action is strong and fast, be difficult to confirm that the long-term prescription treatment can produce drug resistance, in therapeutic process, causes the breakthrough (breakthrough) of ALT and HBV DNA the course of treatment, cause that sb.'s illness took a turn for the worse.And the long-term prescription expense is high.These have all had a strong impact on the rational Application in time extensively of hepatitis B virus resisting medicine, therefore, explore new Therapeutic Method be still essential.
The compound of Chinese medicine chronic hepatitis B has special advantages, and effect below the performance: 1 antiviral, antiviral therapy are the advantages of Chinese medicine.The research of Chinese medicine anti-hepatitis virus receives the attention of domestic medical circle always, and has obtained certain achievement, and like multiple heat and toxic materials clearing away medicine, heat-clearing and diuresis-promoting drug etc., proof has antiviral effect after deliberation.The maximum characteristics of the anti-HBV of Chinese medicine are can not produce drug resistance, can reduce virus load through taking Chinese medicine for a long time, to reach antiviral effect gradually.2 hepatoprotective, modern study prove, the plurality of Chinese effective ingredient the protection hepatocyte, improve aspects such as liver function, transaminase lowering significant effect arranged.3 improve clinical symptoms; Part Chinese medicine such as Qi-tonifying drug, QI regulating medicine, promoting digestion and removing stagnation medicine, drug for invigorating blood circulation and eliminating stasis etc. have good effect for the clinical symptoms of improving the hepatopath such as hepatic region pain, abdominal distention etc. for improving hepatopath's diet situation and alleviating mental pressure.4 promoting the function of the gallbladder to alleviate jaundice, a lot of heat-clearing and toxic substances removing, diuresis are dried, the Chinese medicine of blood circulation promoting and blood stasis dispelling all has the effect of promoting the function of the gallbladder to alleviate jaundice.These medicines can be processed the preparation of the clinical use of multiple confession through different compatible combination, and the good clinical effect is arranged.5 anti-hepatic fibrosis; The anti-hepatic fibrosis treatment is an important component part in the chronic hepatopathy treatment; Drug for invigorating blood circulation and eliminating stasis in the Chinese medicine has certain therapeutical effect for hepatic fibrosis, and some compound Chinese medicinal preparation have been brought into play important effect in the treatment early stage liver cirrhosis clinically.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine of effective treatment hepatitis B; Suppress to greatest extent or elimination HBV; Alleviate necrosis of hepatocyte inflammation and hepatic fibrosis; Delay and stop PD, reduce and prevent that liver from losing the generation of compensatory, liver cirrhosis, HCC and complication thereof, thus make the life better quality with prolong life time.
Another object of the present invention is to provide a kind of preparation method of Chinese medicine of treating hepatitis B.
The present invention accomplishes through following technical proposal: a kind of Chinese medicine of treating hepatitis B is characterized in that being made up of following raw materials by weight percentage:
Ramulus et Folium Rhinacanthi nasuti 20～60%
Herba Rabdosiae Lophanthoidis 20～45
Concha Erosariae seu Cypraeae 7～15%
Rhizoma Polygoni Cuspidati 5～20%
Herba Hedyotidis Diffusae 8～20%.
The Chinese medicine of said treatment hepatitis B, preferred following raw materials by weight percentage combination, curative effect is better:
Ramulus et Folium Rhinacanthi nasuti 40～50%
Herba Rabdosiae Lophanthoidis 25～40%
Concha Erosariae seu Cypraeae 8～12%
Rhizoma Polygoni Cuspidati 7～15%
Herba Hedyotidis Diffusae 10～18%.
Wherein, Ramulus et Folium Rhinacanthi nasuti be acanthaceous plant rhinacanthus nasuta Kurz Rhinacanthus nasutus (L.) Lindau dry aerial parts or the branch, leaf.Main product in Guangxi, Guangdong, Yunnan etc. economize (district), because of its effect just like Ganoderma, floral white, the lip type is given birth on axil or branch top, the white crane that shape such as crowd's exhibition are circled in the air is so " Ramulus et Folium Rhinacanthi nasuti ".The property sweet light flat, mainly go into lung, liver, stomach, all warps of intestine and small intestine.Herb contains chemical constituents such as flavone, phenols, aminoacid, organic acid, tannin.Function with pathogenic fire reducing, profit liver, eliminating inflammation and expelling toxin.Cure mainly hepatopathy, pulmonary tuberculosis, oedema due to nephritis, tinea corporis, eczema.
Herba Rabdosiae Lophanthoidis derives from Labiatae Rabdosia plant Rabdosia lophanthoides Isodon striatus (Benth.) Kudo.For south China medical herbs commonly used among the people, be a kind of herbaceos perennial, because of Gou Xi limit, mountain valley is born in its happiness, fresh blade is rubbed brokenly to be had yellow juice and gains the name.The Herba Rabdosiae Lophanthoidis Herb can be used as medicine, and nature and flavor are bitter cool.Contain compositions such as flavone, aminoacid, organic acid, phenols, terpenoid, tool is antibiotic, the effect of antiinflammatory, reducing fever and protecting liver, activating QI expectorant.Be used to treat acute icterohepatitisshock, acute cholecystitis, chronic hepatitis B, acute cholecystitis etc.
Concha Erosariae seu Cypraeae belongs to medicine for calming liver and calming endopathic wind, and the shell for Cypraeidae animal mauritia arabica (A Wen awards shellfish) Mauritia arabica (Linnaeus) originates in ground such as Hainan Island, Fujian, Taiwan.Nature and flavor are flat, salty, return Liver Channel.Function with suppressing the hyperactive liver and subsiding YANG, tranquillizing the mind by relieving convulsion, liver heat removing and eyesight improving.Cure mainly excessive rising of liver-YANG, disease such as the insomnia of having a dizzy spell, palpitate with fear, conjunctival congestion cataracta.The article of giving birth to quality is hard, is unfavorable for pulverizing, the clinical calcining products of using more.
Rhizoma Polygoni Cuspidati is dry rhizome and the root of polygonaceae plant Rhizoma Polygoni Cuspidati Polygonum cuspidatum Sieb.et Zucc..Rhizoma Polygoni Cuspidati mainly contains diphenylethylene and anthraquinone analog compound, and the former is mainly resveratrol and polydatin (polygonin), has multiple pharmacological effect such as antitumor, blood fat reducing; The latter is representative with emodin, physcione, function such as have anti-bacteria and anti-virus, anti-inflammatory and antalgic, protect the liver.Cold nature, mildly bitter flavor are returned liver, gallbladder, lung meridian.Tool expelling wind and removing dampness, dissipating blood stasis analgesic therapy, relieving cough and resolving phlegm, relievining asthma effect such as protects the liver, and application clinically more and more widely.
Herba Hedyotidis Diffusae is the dry herb of Rubiaceae cerastium plant Herba Hedyotidis Diffusae Oldenlandia diffusa (Willd.) Roxb.Hang down loosely herbaceous plant for annual.Be distributed widely in China southeast and the west and south.Cold in nature, bitter in the mouth, sweet, GUIXIN, liver, spleen channel.Mainly contain compositions such as anthraquinone class, terpenoid, flavonoid, sterols, alkanes, organic acid, polysaccharide.That modern pharmacological research proof has is antibiotic, the effect of antiviral, antiinflammatory, antioxidation, neuroprotective and raising immunity.
Second purpose of the present invention realizes through following technical scheme: a kind of preparation method of Chinese medicine of treating hepatitis B is characterized in that through following process steps:
A, get material by following mass percent:
Ramulus et Folium Rhinacanthi nasuti 20～60%
Herba Rabdosiae Lophanthoidis 20～45%
Concha Erosariae seu Cypraeae 7～15%
Rhizoma Polygoni Cuspidati 5～20%
Herba Hedyotidis Diffusae 8～20%;
B, respectively with the above-mentioned raw materials medicine clean, dry or calcining, grind, mix after, directly incapsulate or allocate into an amount of conventional pharmaceutic adjuvant and process tablet or pill, promptly get the Chinese medicine of treating hepatitis B; Perhaps
C, respectively with water extract-alcohol precipitation or the alcohol extracting-water precipitating of above-mentioned raw materials medicine through routine, the perhaps dipping of water or organic solvent, backflow, diafiltration, perhaps ultrasonic extraction, perhaps CO
2Critical or subcritical extraction method extracts the effective ingredient in the crude drug, allocate an amount of of the prior art conventional pharmaceutic adjuvant again into after, can be prepared into conventional formulations such as capsule, tablet, pill, electuary, drop pill.
The present invention preferably adopts following extraction processing method:
(1) get clean Concha Erosariae seu Cypraeae, put in the refractory container, forging on the smokeless stove fire when entire body is popular in, take out, cool, pulverize is subsequent use;
(2), add water 10-15 for the first time and doubly measure with (1) gained powder and Ramulus et Folium Rhinacanthi nasuti, Herba Rabdosiae Lophanthoidis, Herba Hedyotidis Diffusae decocte with water twice; For the second time add water 10-15 and doubly measure, decocted 1-2 hour at every turn, filter afterwards, merging filtrate is condensed into extractum with filtrating; Add 95% ethanol and make the ethanol content of whole solution system reach 70-90%, hold over night extracts supernatant, and the extractum that precipitates is subsequent use;
The 70-90% alcoholic solution of above-mentioned (2) step gained that (3) adding 4-8 doubly measures in Rhizoma Polygoni Cuspidati in 60-80 ℃ of hot reflux 1-2 hour, filters; The 70-90% alcoholic solution of above-mentioned (2) step that filtering residue reuse 4-8 doubly measures extracted 1-2 hour in 60-80 ℃ of hot reflux, filtered merging filtrate; Filtrate decompression and reclaim ethanol after, extractum subsequent use;
(4) with step (2), (3) gained extractum mix homogeneously, after the adding appropriate amount of auxiliary materials, obtain the medicine grain with wet granulation of the prior art, the reuse conventional method further is prepared into conventional formulations such as granule, tablet or capsule; Perhaps
(5) with step (2), (3) gained extractum spray drying method, get dry extract, be ground into the end through drying under reduced pressure with prior art, mix homogeneously, add appropriate amount of auxiliary materials after, make the medicine grain; The reuse conventional method further is prepared into conventional formulations such as granule, tablet or capsule; Perhaps
(6), after the adding appropriate amount of auxiliary materials,, be prepared into oral liquid with conventional method with dissolved in distilled water with step (2), (3) gained extractum mix homogeneously.
The Chinese medicine of treatment hepatitis B provided by the invention has the effect of the liver and the kidney tonifying, removing liver heat and toxic substances, suppressing the hyperactive liver and subsiding YANG.Can duplicate, alleviate liver inflammation and necrosis, its fibrosis of protection hepatocyte prevention, promote liver cell regeneration, delay and stop the continuation of the state of an illness to worsen (as showing effect, cause liver cirrhosis, hepatocarcinoma etc. repeatedly) by anti-hepatitis virus, thereby improve the quality of life and prolongation time-to-live of hepatitis B patient.The present invention utilizes the traditional Chinese medical science original prescription theory and Therapeutic Principle, and reasonable formula is with pure oral preparation of Chinese traditional medicinal treatment hepatitis B, safe, easy, determined curative effect.Can be prepared into peroral dosage forms such as granule, tablet, capsule, oral liquid as required, easy to use.The method for preparing of peroral dosage form of the present invention is scientific and reasonable, and effective ingredient runs off few, and extraction ratio is high.
The specific embodiment
Embodiment 1
A, get material by following prescription: Ramulus et Folium Rhinacanthi nasuti 40g,, Herba Rabdosiae Lophanthoidis 30g,, Concha Erosariae seu Cypraeae 10g, Rhizoma Polygoni Cuspidati 8g, Herba Hedyotidis Diffusae 12g;
B, the following preparation technology of process:
(1) get clean Concha Erosariae seu Cypraeae, put in the refractory container, forging on the smokeless stove fire when entire body is popular in, take out, cool, pulverize is subsequent use.
(2) with (1) gained Concha Erosariae seu Cypraeae powder with after Ramulus et Folium Rhinacanthi nasuti, Herba Rabdosiae Lophanthoidis, Herba Hedyotidis Diffusae mix, decocte with water twice adds 1200ml water for the first time; For the second time add same 1200ml water, decocted 1.5 hours at every turn, filter, merging filtrate is condensed into extractum with filtrating; Adding concentration and be 95% ethanol makes the ethanol content of whole solution system reach 80%, hold over night; Extract supernatant, the extractum that precipitates is subsequent use;
(3) 80% alcoholic solution of adding 48ml step (2) in Rhizoma Polygoni Cuspidati in 70 ℃ of hot refluxs 2 hours, filters; 80% alcoholic solution of filtering residue reuse 48ml step (2) extracted 2 hours in 70 ℃ of hot refluxs, filters, and merging filtrate, behind the decompression filtrate recycling ethanol, it is subsequent use to get extractum;
(4) with step (2), (3) gained extractum mix homogeneously, after the adding appropriate amount of starch, wet granulation obtains medicine-containing particle, gets granule after the dry packing; Tabletting is processed tablet after perhaps in medicine-containing particle, adding an amount of Pulvis Talci, magnesium stearate; Can also in medicine-containing particle, add an amount of Pulvis Talci, incapsulate and make capsule; Perhaps add benzoic acid,, add simple syrup to full dose and be prepared into oral liquid with dissolved in distilled water.
Embodiment 2
A, get material: Ramulus et Folium Rhinacanthi nasuti 50g, Herba Rabdosiae Lophanthoidis 20g, Concha Erosariae seu Cypraeae 15g, Rhizoma Polygoni Cuspidati 5g, Herba Hedyotidis Diffusae 10g by following prescription;
B, through following preparation technology:
(1) get clean Concha Erosariae seu Cypraeae, put in the refractory container, forging on the smokeless stove fire when entire body is popular in, take out, cool, pulverize is subsequent use;
(2) decocte with water twice in (1) gained Concha Erosariae seu Cypraeae powder and Ramulus et Folium Rhinacanthi nasuti, Herba Rabdosiae Lophanthoidis, Herba Hedyotidis Diffusae adds water 1000ml for the first time; For the second time add water 1000ml, decocted 2 hours at every turn, filter, merging filtrate is condensed into extractum with filtrating; Add concentration and be 95% ethanol and make the ethanol content of whole solution system reach 70%, hold over night extracts supernatant, and the extractum that precipitates is subsequent use;
(3) 70% alcoholic solution of adding 25ml step (2) in Rhizoma Polygoni Cuspidati in 80 ℃ of hot refluxs 2 hours, filters; 70% alcoholic solution of 5 times of amounts of filtering residue reuse extracted 2 hours in 80 ℃ of hot refluxs, filtered merging filtrate; It is subsequent use that decompression filtrate recycling ethanol gets extractum;
(4) step (2), (3) gained extractum are flung to moisture content through spray drying and are got dry extract, be ground into powder, mix homogeneously, add an amount of crystallite after, dry granulation gets medicine-containing particle; Get granule after the packing; Tabletting is processed tablet after perhaps in medicine-containing particle, adding an amount of Pulvis Talci, magnesium stearate; Can also in medicine-containing particle, add an amount of Pulvis Talci, be packed into capsule and make capsule.
Embodiment 3
A, get material: Ramulus et Folium Rhinacanthi nasuti 20g, Herba Rabdosiae Lophanthoidis 40g, Concha Erosariae seu Cypraeae 7g, Rhizoma Polygoni Cuspidati 20g, Herba Hedyotidis Diffusae 13g by following prescription;
B, the following preparation technology of process:
(1) get clean Concha Erosariae seu Cypraeae, put in the refractory container, forging on the smokeless stove fire when entire body is popular in, take out, cool, pulverize is subsequent use;
(2), add 15 times of amounts of water for the first time with (1) gained powder and Ramulus et Folium Rhinacanthi nasuti, Herba Rabdosiae Lophanthoidis, Herba Hedyotidis Diffusae decocte with water twice.For the second time add 15 times of amounts of water, decocted 1 hour at every turn, filter, merging filtrate is condensed into thick extractum with filtrating.Add 95% ethanol and make the ethanol content 85% of whole solution system, hold over night.Extract supernatant, the extractum that precipitates is subsequent use;
(3) Rhizoma Polygoni Cuspidati adds 85% alcoholic solution of 8 times of amounts, in 60 ℃ of hot refluxs 1 hour, filters.85% alcoholic solution of 8 times of amounts of filtering residue reuse extracted 1 hour in 60 ℃ of hot refluxs, filtered merging filtrate.It is subsequent use that decompression filtrate recycling ethanol gets extractum;
(4) step (2) (3) gained extractum is mixed, add benzoic acid,, add simple syrup to full dose and be prepared into oral liquid with dissolved in distilled water.
The adjuvant that the present invention adds in middle article of preparation and patent medicine process is pharmaceutic adjuvant.For example: Pulvis Talci, magnesium stearate are lubricant, help after the interpolation that tablet breaks away from and filled capsules smoothly from mould; Microcrystalline cellulose can strengthen the plasticity of medicine, is convenient to direct compression; Benzoic acid is an antiseptic.The addition of adjuvant is the usual amounts of pharmaceutical field.
For showing effect of the present invention, explain through the zoopery report below.
1 materials and methods
1.1 healthy SD rat, male and female half and half, scale of construction 180-220g are selected in experiment for use.
1.2 medical material and main agents
Get the oral liquid subsequent use (the 1ml oral liquid is equivalent to the 1g crude drug) of the embodiment of the invention 1; ALT, AST determination experiment box are available from Shanghai Biological Products Inst., Ministry of Public Health; All the other reagent are homemade analytical pure.
1.3 method
Get 50 of SD rats, be divided into 5 groups of matched groups, model group, low dose of administration group, middle dosed administration group, heavy dose of administration group at random, 10 every group.Except that the normal control group, all the other respectively organize equal subcutaneous injection 25%CCl
4Vegetable oil solution 2ml/kg, matched group is in appearance vegetable oil such as same area injections.2 times weekly, continuous 3 months.Modeling simultaneously, matched group, model group are irritated stomach 0.9% normal saline 5ml/kg every day.The gastric infusion dosage of each the administration group dose of making a living, low dose of administration group 1g/kg/d, middle dosed administration group 2g/kg/d, high dose administration group 4g/kg/d are diluted to the oral liquid of preparation with the normal saline isometric(al) and use.Administration every day 1 time, continuous 3 months.Behind the last administration 1h, eye socket is got blood, separation of serum.Measure Serum ALT, AST biochemical indicator amount with automatic clinical chemistry analyzer.Take off cervical vertebra then and put to death animal, cut open and get liver and weigh, calculate the ponderal index of liver.
1.4 statistical procedures
Data are carried out statistical analysis through SPSS 12.0 statistical softwares, carry out the t significance test with x ± s.
2 results
2.1 table 1 is seen in the influence to Serum ALT, AST.
Table 1 couple CCl
4Due to chronic hepatic injury rat blood serum ALT, the active influence of AST (x ± s, N=10)
With liver injury model group comparison * P < 0.05**P < 0.01 (same down)
2.2 table 2 is seen in the influence to the ponderal index of liver.
Table 2 couple CCl
4Due to chronic hepatic injury rat liver ponderal index influence (x ± s, N=10)
Hepatic injury is the complex process of multifactor participation, uses CCl
4Inductive hepatic injury is classical Liver Fibrosis Model.CCl
4After getting into body lipid peroxidation takes place in hepatomicrosome mainly, cause the infringement of liver plasma membrane 26S Proteasome Structure and Function, make that ALT, AST overflow in the cell, cause ALT in the blood, AST is active raises, the hepatic injury zone is big more, and ALT, AST activity are high more.Observe in this experiment, oral liquid can improve CCl
4The chronic hepatic injury that causes, different therapeutic doses all can make Serum ALT, AST reduce, and middle high dose alleviates the liver weight index.Explain according to the present invention's made oral liquid of filling a prescription and to alleviate CCl
4To the substantive chronic lesion of hepatic tissue, have significantly the liver protecting and ALT lowering effect, and the pathological change that alleviates liver tissue fibrosis.
Claims (3)
1. Chinese medicine of treating hepatitis B is characterized in that being made up of following raw materials by weight percentage:
2. preparation method of Chinese medicine of treating hepatitis B is characterized in that through the following step:
A, get material by following mass percent:
B, respectively with the above-mentioned raw materials medicine clean, dry or calcining, grind, mix after, directly incapsulate or allocate into an amount of conventional pharmaceutic adjuvant and process tablet or pill, promptly get the Chinese medicine of treating hepatitis B.
3. preparation method of Chinese medicine of treating hepatitis B is characterized in that through the following step:
A, get material by following mass percent:
B, respectively the above-mentioned raw materials medicine is passed through:
(1) get clean Concha Erosariae seu Cypraeae, put in the refractory container, forging on the smokeless stove fire when entire body is popular in, take out, cool, pulverize is subsequent use;
(2), add water 10-15 for the first time and doubly measure with (1) gained powder and Ramulus et Folium Rhinacanthi nasuti, Herba Rabdosiae Lophanthoidis, Herba Hedyotidis Diffusae decocte with water twice; For the second time add water 10-15 and doubly measure, decocted 1-2 hour at every turn, filter afterwards, merging filtrate is condensed into extractum with filtrating; Add 95% ethanol and make the ethanol content of whole solution system reach 70-90%, hold over night extracts supernatant, and the extractum that precipitates is subsequent use;
The 70-90% alcoholic solution of above-mentioned (2) step gained that (3) adding 4-8 doubly measures in Rhizoma Polygoni Cuspidati in 60-80 ℃ of hot reflux 1-2 hour, filters; The 70-90% alcoholic solution of above-mentioned (2) step that filtering residue reuse 4-8 doubly measures extracted 1-2 hour in 60-80 ℃ of hot reflux, filtered merging filtrate; Filtrate decompression and reclaim ethanol after, extractum subsequent use;
(4) with step (2), (3) gained extractum mix homogeneously, after the adding appropriate amount of auxiliary materials, obtain the medicine grain through wet granulation, the reuse conventional method further is prepared into granule, tablet or capsule;
Perhaps
(5) with step (2), (3) gained extractum is spray-dried or drying under reduced pressure gets dry extract, and is ground into the end, mix homogeneously, add appropriate amount of auxiliary materials after, make the medicine grain; The reuse conventional method further is prepared into granule, tablet or capsule;
Perhaps
(6), after the adding appropriate amount of auxiliary materials,, be prepared into oral liquid through conventional method with dissolved in distilled water with step (2), (3) gained extractum mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102335220A CN101390970B (en) | 2008-11-03 | 2008-11-03 | Traditional Chinese medicine for treating hepatitis B and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102335220A CN101390970B (en) | 2008-11-03 | 2008-11-03 | Traditional Chinese medicine for treating hepatitis B and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101390970A CN101390970A (en) | 2009-03-25 |
| CN101390970B true CN101390970B (en) | 2012-01-11 |
Family
ID=40491611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102335220A Expired - Fee Related CN101390970B (en) | 2008-11-03 | 2008-11-03 | Traditional Chinese medicine for treating hepatitis B and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101390970B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106930B (en) * | 2009-12-28 | 2012-07-18 | 味全食品工业股份有限公司 | Mixture with antioxidant and liver-protecting functions and manufacturing method thereof |
| CN103356749A (en) * | 2013-07-19 | 2013-10-23 | 苏州市天灵中药饮片有限公司 | Subcritical water extraction process of shuanghuanglian |
| CN105287653B (en) * | 2014-06-26 | 2019-03-26 | 富裔实业股份有限公司 | The purposes of liver-cancer medicine is used to prepare comprising the Chinese herbal medicine extract of Antrodia camphorata, Phellinus mushroom and bignose rhinacanthus branchlet and leaf |
| CN105213489A (en) * | 2015-11-19 | 2016-01-06 | 代文涛 | A kind ofly be used for the treatment of medicine pill of hepatitis B type liver cirrhosis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1108943A (en) * | 1994-03-21 | 1995-09-27 | 李春祥 | Medicine "Yigankang" for hepatitis B and its preparation |
| CN1426785A (en) * | 2001-12-15 | 2003-07-02 | 彭加田 | Chinese medicinal herbs prescription for treating hepatitis B |
-
2008
- 2008-11-03 CN CN2008102335220A patent/CN101390970B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1108943A (en) * | 1994-03-21 | 1995-09-27 | 李春祥 | Medicine "Yigankang" for hepatitis B and its preparation |
| CN1426785A (en) * | 2001-12-15 | 2003-07-02 | 彭加田 | Chinese medicinal herbs prescription for treating hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101390970A (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103990081A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN104083727A (en) | Traditional Chinese medicine composition for nourishing and protecting liver | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN105012452A (en) | New application of clausena lansium leaves | |
| CN102475830B (en) | Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102228547B (en) | Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN101983695A (en) | Traditional Chinese medicine composition for curing hemiplegia and preparation method thereof | |
| CN111358906B (en) | Traditional Chinese medicine composition suitable for exogenous diseases | |
| CN103446445A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN105477465A (en) | Chinese herb preparation with liver protection function and preparing technology of Chinese herb preparation | |
| CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
| CN103405660B (en) | Compound medicine for treating headache | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN105012642B (en) | A kind of promoting blood circulation and removing blood stasis, preparation method of the Chinese medicine composition of hemostasis and pain-relieving | |
| CN104998019B (en) | A kind of promoting blood circulation and removing blood stasis, Chinese medicine composition of hemostasis and pain-relieving | |
| CN102451274A (en) | Leatherleaf-mahonia-containing Chinese medicinal preparation for reducing internal heat | |
| CN110742983B (en) | Traditional Chinese medicine preparation for treating acute gout attack and preparation method thereof | |
| CN104398564A (en) | Tripterygium wilfordii containing Chinese medicinal composition for treatment of gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120111 Termination date: 20141103 |
|
| EXPY | Termination of patent right or utility model |